{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:29:10Z","timestamp":1791725350557,"version":"4.3.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T00:00:00Z","timestamp":1657929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T00:00:00Z","timestamp":1657929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To report the long-term outcomes of Ru-106 plaque radiotherapy in eyes with uveal melanoma (UM) and to assess the effect of tumor thickness and location on final outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Medical records of 234 patients undergoing Ru-106 plaque radiotherapy for UM were reviewed, and the visual outcome, globe preservation, and patient survival were evaluated. The results of 2 groups were compared: 1. between thin (small and medium-sized, thickness\u2009&lt;\u20097\u2009mm, 148 eyes [63.2%]) and thick (thickness\u2009\u2265\u20097\u2009mm, 86 eyes [36.8%]) tumors, and 2. between large (largest basal diameter [LBD]\u2009&gt;\u200912\u2009mm, 109 eyes [46.6%]) and medium\/small (LBD\u2009\u2264\u200912\u2009mm, 125 eyes [53.4%]). In addition, a comparison of the juxtapapillary location in 46 eyes (19.7%) versus tumors arising elsewhere and between tumors with and without ciliary involvement in 48 eyes (21.5%) were done.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The patients were followed for a median of 54.2\u2009months (range: 6\u2013194.5\u2009months). After adjusting for baseline visual acuity (VA), there was no significant association between final VA and different dimension and tumor location groups. Final globe preservation was 91.9%, and there was no significant difference between different dimension- and ciliary body involvement groups regarding anatomical success rate. The juxtapapillary tumors had lower globe preservation (80.4% vs .94.7%, <jats:italic>p<\/jats:italic>\u2009=\u20090.002). The hazard ratio (HR) for enucleation in juxtapapillary tumors was HR\u2009=\u20096.58 (95-CI: 3.84 to 11.21). The overall metastasis rate was 6.8%, with no significant difference in juxtapapillary tumors (4.3% vs.7.4%, <jats:italic>p<\/jats:italic>\u2009=\u20090.455).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Ru-106 plaque radiotherapy is an effective treatment for thick and large UM. With this type of treatment, the globe preservation rate is lower in juxtapapillary tumors, but there is no significant difference in the metastasis rate.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12886-022-02521-9","type":"journal-article","created":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T22:02:28Z","timestamp":1658008948000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Ruthenium-106 plaque radiotherapy for uveal melanoma: analysis of tumor dimension and location on anatomical and functional results"],"prefix":"10.1186","volume":"22","author":[{"given":"Reza","family":"Mirshahi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahad","family":"Sedaghat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Jaberi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohreh","family":"Azma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Mazloumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masood","family":"Naseripour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,16]]},"reference":[{"key":"2521_CR1","doi-asserted-by":"publisher","first-page":"e169","DOI":"10.1016\/j.prro.2014.09.005","volume":"5","author":"V Takiar","year":"2015","unstructured":"Takiar V, et al. A choice of radionuclide: comparative outcomes and toxicity of ruthenium-106 and iodine-125 in the definitive treatment of uveal melanoma. Practical radiation oncology. 2015;5:e169\u201376.","journal-title":"Practical radiation oncology"},{"key":"2521_CR2","first-page":"5281","volume":"17","author":"A Bela\u00efd","year":"2016","unstructured":"Bela\u00efd A, et al. Brachytherapy of uveal melanomas with Ruthenium-106 plaques. Asian Pacific journal of cancer prevention: APJCP. 2016;17:5281.","journal-title":"Asian Pacific journal of cancer prevention: APJCP"},{"key":"2521_CR3","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3857\/roj.2020.00318","volume":"38","author":"M Sayan","year":"2020","unstructured":"Sayan M, et al. Clinical management of uveal melanoma: a comprehensive review with a treatment algorithm. Radiat Oncol J. 2020;38:162\u20139. https:\/\/doi.org\/10.3857\/roj.2020.00318.","journal-title":"Radiat Oncol J"},{"key":"2521_CR4","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1097\/IAE.0000000000002169","volume":"39","author":"EB Turkoglu","year":"2019","unstructured":"Turkoglu EB, Pointdujour-Lim R, Mashayekhi A, Shields CL. Photodynamic therapy as primary treatment for small choroidal melanoma. Retina. 2019;39:1319\u201325. https:\/\/doi.org\/10.1097\/IAE.0000000000002169.","journal-title":"Retina"},{"key":"2521_CR5","volume-title":"In radiotherapy of intraocular and orbital tumors 23\u201330","author":"PK Lommatzsch","year":"1993","unstructured":"Lommatzsch PK. In radiotherapy of intraocular and orbital tumors 23\u201330: Springer; 1993."},{"key":"2521_CR6","doi-asserted-by":"publisher","unstructured":"Papageorgiou, K. I., Cohen, V. M. L., Bunce, C., Kinsella, M. & Hungerford, J. L. Predicting local control of choroidal melanomas following <sup>106<\/sup>Ru plaque brachytherapy. Br J Ophthalmol 95, 166, doi:https:\/\/doi.org\/10.1136\/bjo.2009.176198 (2011).","DOI":"10.1136\/bjo.2009.176198"},{"key":"2521_CR7","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13014-020-01621-4","volume":"15","author":"P Jiang","year":"2020","unstructured":"Jiang P, et al. 106Ruthenium eye plaque brachytherapy in the management of medium sized uveal melanoma. Radiat Oncol. 2020;15:183. https:\/\/doi.org\/10.1186\/s13014-020-01621-4.","journal-title":"Radiat Oncol"},{"key":"2521_CR8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.5114\/jcb.2016.57818","volume":"8","author":"M Naseripour","year":"2016","unstructured":"Naseripour M, et al. Ruthenium-106 brachytherapy for thick uveal melanoma: reappraisal of apex and base dose radiation and dose rate. J Contemp Brachytherapy. 2016;8:66\u201373. https:\/\/doi.org\/10.5114\/jcb.2016.57818.","journal-title":"J Contemp Brachytherapy"},{"key":"2521_CR9","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/BF00165952","volume":"230","author":"E Messmer","year":"1992","unstructured":"Messmer E, Bornfeld N, Foerster M, Schilling H, Wessing A. Histopathologic findings in eyes treated with a ruthenium plaque for uveal melanoma. Graefes Arch Clin Exp Ophthalmol. 1992;230:391\u20136. https:\/\/doi.org\/10.1007\/BF00165952.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2521_CR10","doi-asserted-by":"publisher","first-page":"8081","DOI":"10.3390\/app10228081","volume":"10","author":"G Broggi","year":"2020","unstructured":"Broggi G, et al. Histopathology and genetic biomarkers of choroidal melanoma. Appl Sci. 2020;10:8081.","journal-title":"Appl Sci"},{"key":"2521_CR11","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.ajo.2004.07.006","volume":"138","author":"BS Hawkins","year":"2004","unstructured":"Hawkins BS. & collaborative ocular melanoma Study, G. the collaborative ocular melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24. Am J Ophthalmol. 2004;138:936\u201351. https:\/\/doi.org\/10.1016\/j.ajo.2004.07.006.","journal-title":"Am J Ophthalmol"},{"key":"2521_CR12","doi-asserted-by":"publisher","unstructured":"Gelmi MC, et al. Adding the Cancer genome atlas chromosome classes to American joint committee on Cancer system offers more precise prognostication in uveal melanoma. Ophthalmology. 2021. https:\/\/doi.org\/10.1016\/j.ophtha.2021.11.018.","DOI":"10.1016\/j.ophtha.2021.11.018"},{"key":"2521_CR13","first-page":"805","volume-title":"AJCC Cancer Staging Manual","author":"T Kivel\u00e4","year":"2016","unstructured":"Kivel\u00e4 T, Simpson RE, Grossniklaus HE, et al. AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2016. p. 805\u201317.","edition":"8"},{"key":"2521_CR14","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/0002-9394(88)90237-1","volume":"105","author":"JL Kinyoun","year":"1988","unstructured":"Kinyoun JL, Chittum ME, Wells CG. Photocoagulation treatment of radiation retinopathy. Am J Ophthalmol. 1988;105:470\u20138. https:\/\/doi.org\/10.1016\/0002-9394(88)90237-1.","journal-title":"Am J Ophthalmol"},{"key":"2521_CR15","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ophtha.2013.08.039","volume":"121","author":"SU Shah","year":"2014","unstructured":"Shah SU, et al. Intravitreal bevacizumab at 4-month intervals for prevention of macular edema after plaque radiotherapy of uveal melanoma. Ophthalmology. 2014;121:269\u201375. https:\/\/doi.org\/10.1016\/j.ophtha.2013.08.039.","journal-title":"Ophthalmology"},{"key":"2521_CR16","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1136\/bjophthalmol-2014-305055","volume":"98","author":"M Fili","year":"2014","unstructured":"Fili M, Lundell G, Lundell M, Seregard S. High dose rate and low dose rate ruthenium brachytherapy for uveal melanoma. No association with ocular outcome. Br J Ophthalmol. 2014;98:1349\u201354. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305055.","journal-title":"Br J Ophthalmol"},{"key":"2521_CR17","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1159\/000479558","volume":"4","author":"E Stockel","year":"2018","unstructured":"Stockel E, et al. Dose distributions and treatment margins in ocular brachytherapy with 106Ru eye plaques. Ocul Oncol Pathol. 2018;4:122\u20138. https:\/\/doi.org\/10.1159\/000479558.","journal-title":"Ocul Oncol Pathol"},{"key":"2521_CR18","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1001\/archopht.120.7.933","volume":"120","author":"CL Shields","year":"2002","unstructured":"Shields CL, et al. Combined plaque radiotherapy and transpupillary thermotherapy for choroidal melanoma: tumor control and treatment complications in 270 consecutive patients. Arch Ophthalmol. 2002;120:933\u201340. https:\/\/doi.org\/10.1001\/archopht.120.7.933.","journal-title":"Arch Ophthalmol"},{"key":"2521_CR19","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.radonc.2010.03.023","volume":"95","author":"KM Verschueren","year":"2010","unstructured":"Verschueren KM, et al. Long-term outcomes of eye-conserving treatment with ruthenium (106) brachytherapy for choroidal melanoma. Radiother Oncol. 2010;95:332\u20138. https:\/\/doi.org\/10.1016\/j.radonc.2010.03.023.","journal-title":"Radiother Oncol"},{"key":"2521_CR20","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ijrobp.2005.02.017","volume":"63","author":"B Damato","year":"2005","unstructured":"Damato B, Patel I, Campbell IR, Mayles HM, Errington RD. Local tumor control after 106Ru brachytherapy of choroidal melanoma. Int J Radiat Oncol Biol Phys. 2005;63:385\u201391. https:\/\/doi.org\/10.1016\/j.ijrobp.2005.02.017.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2521_CR21","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.ajo.2003.12.032","volume":"137","author":"F Rouberol","year":"2004","unstructured":"Rouberol F, et al. Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years' experience with beta-rays). Am J Ophthalmol. 2004;137:893\u2013900. https:\/\/doi.org\/10.1016\/j.ajo.2003.12.032.","journal-title":"Am J Ophthalmol"},{"key":"2521_CR22","first-page":"280","volume":"11","author":"S Frenkel","year":"2009","unstructured":"Frenkel S, Hendler K, Pe'er J. Uveal melanoma in Israel in the last two decades: characterization, treatment and prognosis. Isr Med Assoc J. 2009;11:280\u20135.","journal-title":"Isr Med Assoc J"},{"key":"2521_CR23","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S0161-6420(99)90456-6","volume":"106","author":"MW Wilson","year":"1999","unstructured":"Wilson MW, Hungerford JL. Comparison of episcleral plaque and proton beam radiation therapy for the treatment of choroidal melanoma. Ophthalmology. 1999;106:1579\u201387. https:\/\/doi.org\/10.1016\/S0161-6420(99)90456-6.","journal-title":"Ophthalmology"},{"key":"2521_CR24","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1136\/bjo.2009.157701","volume":"93","author":"N Kaiserman","year":"2009","unstructured":"Kaiserman N, Kaiserman I, Hendler K, Frenkel S, Pe\u2019er, J. Ruthenium-106 plaque brachytherapy for thick posterior uveal melanomas. Br J Ophthalmol. 2009;93:1167\u201371. https:\/\/doi.org\/10.1136\/bjo.2009.157701.","journal-title":"Br J Ophthalmol"},{"key":"2521_CR25","doi-asserted-by":"publisher","unstructured":"Ophthalmic oncology task, F. local recurrence significantly increases the risk of metastatic uveal melanoma. Ophthalmology. 2016;123:86\u201391. https:\/\/doi.org\/10.1016\/j.ophtha.2015.09.014.","DOI":"10.1016\/j.ophtha.2015.09.014"},{"key":"2521_CR26","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1007\/s00417-017-3703-0","volume":"255","author":"JV Hegde","year":"2017","unstructured":"Hegde JV, et al. Juxtapapillary and circumpapillary choroidal melanoma: globe-sparing treatment outcomes with iodine-125 notched plaque brachytherapy. Graefes Arch Clin Exp Ophthalmol. 2017;255:1843\u201350. https:\/\/doi.org\/10.1007\/s00417-017-3703-0.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2521_CR27","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1001\/archopht.126.11.1515","volume":"126","author":"MS Sagoo","year":"2008","unstructured":"Sagoo MS, et al. Plaque radiotherapy for juxtapapillary choroidal melanoma overhanging the optic disc in 141 consecutive patients. Arch Ophthalmol. 2008;126:1515\u201322. https:\/\/doi.org\/10.1001\/archopht.126.11.1515.","journal-title":"Arch Ophthalmol"},{"key":"2521_CR28","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.ijrobp.2005.02.059","volume":"63","author":"B Damato","year":"2005","unstructured":"Damato B, Patel I, Campbell IR, Mayles HM, Errington RD. Visual acuity after ruthenium (106) brachytherapy of choroidal melanomas. Int J Radiat Oncol Biol Phys. 2005;63:392\u2013400. https:\/\/doi.org\/10.1016\/j.ijrobp.2005.02.059.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2521_CR29","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/s0161-6420(00)00526-1","volume":"108","author":"BM Melia","year":"2001","unstructured":"Melia BM, et al. Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report no. 16. Ophthalmology. 2001;108:348\u201366. https:\/\/doi.org\/10.1016\/s0161-6420(00)00526-1.","journal-title":"Ophthalmology"},{"key":"2521_CR30","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1136\/bjo.80.8.732","volume":"80","author":"P Summanen","year":"1996","unstructured":"Summanen P, et al. Radiation related complications after ruthenium plaque radiotherapy of uveal melanoma. Br J Ophthalmol. 1996;80:732\u20139. https:\/\/doi.org\/10.1136\/bjo.80.8.732.","journal-title":"Br J Ophthalmol"},{"key":"2521_CR31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ijrobp.2005.01.022","volume":"63","author":"AW Jensen","year":"2005","unstructured":"Jensen AW, et al. Radiation complications and tumor control after 125I plaque brachytherapy for ocular melanoma. Int J of Rad Oncol*Bio*Phys. 2005;63:101\u20138. https:\/\/doi.org\/10.1016\/j.ijrobp.2005.01.022.","journal-title":"Int J of Rad Oncol*Bio*Phys"},{"key":"2521_CR32","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/0360-3016(86)90315-9","volume":"12","author":"RP Muller","year":"1986","unstructured":"Muller RP, Busse H, Potter R, Kroll P, Haverkamp U. Results of high dose 106-ruthenium irradiation of choroidal melanomas. Int J Radiat Oncol Biol Phys. 1986;12:1749\u201355. https:\/\/doi.org\/10.1016\/0360-3016(86)90315-9.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2521_CR33","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00417-017-3834-3","volume":"256","author":"A Mahdjoubi","year":"2018","unstructured":"Mahdjoubi A, et al. Intravitreal bevacizumab for neovascular glaucoma in uveal melanoma treated by proton beam therapy. Graefes Arch Clin Exp Ophthalmol. 2018;256:411\u201320. https:\/\/doi.org\/10.1007\/s00417-017-3834-3.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2521_CR34","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.sjopt.2013.06.014","volume":"27","author":"B Damato","year":"2013","unstructured":"Damato B, Kacperek A, Errington D, Heimann H. Proton beam radiotherapy of uveal melanoma. Saudi J Ophthalmol. 2013;27:151\u20137. https:\/\/doi.org\/10.1016\/j.sjopt.2013.06.014.","journal-title":"Saudi J Ophthalmol"},{"key":"2521_CR35","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/s0002-9394(00)00385-8","volume":"130","author":"K Gunduz","year":"2000","unstructured":"Gunduz K, Shields CL, Shields JA, Cater J, Brady L. Plaque radiotherapy for management of ciliary body and choroidal melanoma with extraocular extension. Am J Ophthalmol. 2000;130:97\u2013102. https:\/\/doi.org\/10.1016\/s0002-9394(00)00385-8.","journal-title":"Am J Ophthalmol"},{"key":"2521_CR36","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/ICO.0000000000000716","volume":"35","author":"M Naseripour","year":"2016","unstructured":"Naseripour M, et al. Corneal patch graft: a new approach for scleral necrosis secondary to plaque radiotherapy. Cornea. 2016;35:565\u20138. https:\/\/doi.org\/10.1097\/ICO.0000000000000716.","journal-title":"Cornea"},{"key":"2521_CR37","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.ophtha.2012.10.021","volume":"120","author":"S Kaliki","year":"2013","unstructured":"Kaliki S, et al. Scleral necrosis after plaque radiotherapy of uveal melanoma: a case-control study. Ophthalmology. 2013;120:1004\u201311. https:\/\/doi.org\/10.1016\/j.ophtha.2012.10.021.","journal-title":"Ophthalmology"},{"key":"2521_CR38","doi-asserted-by":"publisher","unstructured":"Collaborative Ocular Melanoma Study, G. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol 124, 1684\u20131693, doi:https:\/\/doi.org\/10.1001\/archopht.124.12.1684 (2006).","DOI":"10.1001\/archopht.124.12.1684"},{"key":"2521_CR39","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1136\/bjophthalmol-2012-302584","volume":"97","author":"HJ Kwon","year":"2013","unstructured":"Kwon HJ, Ko JS, Kim M, Lee CS, Lee SC. Prognosis of choroidal melanoma and the result of ruthenium brachytherapy combined with transpupillary thermotherapy in Korean patients. Br J Ophthalmol. 2013;97:653\u20138. https:\/\/doi.org\/10.1136\/bjophthalmol-2012-302584.","journal-title":"Br J Ophthalmol"},{"key":"2521_CR40","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.joco.2015.09.002","volume":"27","author":"M Naseripour","year":"2015","unstructured":"Naseripour M, et al. Monosomy 3 by chromogenic in situ hybridization (CISH) in Iranian patients with uveal melanoma. J Curr Ophthalmol. 2015;27:41\u20135. https:\/\/doi.org\/10.1016\/j.joco.2015.09.002.","journal-title":"J Curr Ophthalmol"},{"key":"2521_CR41","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1159\/000512738","volume":"7","author":"P Manchegowda","year":"2021","unstructured":"Manchegowda P, et al. Uveal melanoma in Asians: a review. Ocul Oncol Pathol. 2021;7:159\u201367. https:\/\/doi.org\/10.1159\/000512738.","journal-title":"Ocul Oncol Pathol"},{"key":"2521_CR42","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.sjopt.2009.05.003","volume":"23","author":"AH Alsuhaibani","year":"2009","unstructured":"Alsuhaibani AH. Uveal melanoma in the Saudi Arabian population: two decades of management at the king Khaled eye specialist hospital. Saudi J Ophthalmol. 2009;23:157\u201363. https:\/\/doi.org\/10.1016\/j.sjopt.2009.05.003.","journal-title":"Saudi J Ophthalmol"},{"key":"2521_CR43","doi-asserted-by":"publisher","first-page":"186","DOI":"10.5146\/tjpath.2015.01357","volume":"32","author":"A Zewar","year":"2016","unstructured":"Zewar A, et al. Management and outcome of uveal melanoma in a single tertiary Cancer Center in Jordan. Turk Patoloji Derg. 2016;32:186\u201392. https:\/\/doi.org\/10.5146\/tjpath.2015.01357.","journal-title":"Turk Patoloji Derg"},{"key":"2521_CR44","doi-asserted-by":"publisher","unstructured":"Mruthyunjaya, P. et al. Association between tumor regression rate and gene expression profile after iodine 125 plaque radiotherapy for uveal melanoma. Ophthalmology 124, 1532\u20131539, doi:https:\/\/doi.org\/https:\/\/doi.org\/10.1016\/j.ophtha.2017.04.013 (2017).","DOI":"10.1016\/j.ophtha.2017.04.013"},{"key":"2521_CR45","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1001\/archopht.123.12.1639","volume":"123","author":"M Diener-West","year":"2005","unstructured":"Diener-West M, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: collaborative ocular melanoma Study group report no. 26. Arch Ophthalmol. 2005;123:1639\u201343. https:\/\/doi.org\/10.1001\/archopht.123.12.1639.","journal-title":"Arch Ophthalmol"},{"key":"2521_CR46","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1001\/jamaophthalmol.2018.3881","volume":"136","author":"CL Shields","year":"2018","unstructured":"Shields CL, et al. Visual outcome and millimeter incremental risk of metastasis in 1780 patients with small choroidal melanoma managed by plaque radiotherapy. JAMA Ophthalmol. 2018;136:1325\u201333. https:\/\/doi.org\/10.1001\/jamaophthalmol.2018.3881.","journal-title":"JAMA Ophthalmol"},{"key":"2521_CR47","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/CMR.0000000000000575","volume":"29","author":"ES Rantala","year":"2019","unstructured":"Rantala ES, Hernberg M, Kivela TT. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res. 2019;29:561\u20138. https:\/\/doi.org\/10.1097\/CMR.0000000000000575.","journal-title":"Melanoma Res"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-022-02521-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-022-02521-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-022-02521-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T22:02:34Z","timestamp":1658008954000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-022-02521-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,16]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2521"],"URL":"https:\/\/doi.org\/10.1186\/s12886-022-02521-9","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,16]]},"assertion":[{"value":"15 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the local Ethics Review Committee of Iran University of Medical Sciences, and all participants provided written informed consent prior to inclusion. The study was conducted in accordance with the tenets of the declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"309"}}